The study concluded that administering CBD oil to dogs with osteoarthritis increased both comfort and activity.
Both children and adults that received CBD, in conjunction with their traditional anti-epileptic medications, experienced a significant decrease in drop seizures during the trial with minimal adverse effects.
A trial study conducted by researchers, encompassing 30 clinical centers worldwide, studied the effects of CBD in 225 Lennox-Gastaut Syndrome patients aged 2 to 55. Lennox-Gastaut Syndrome is a severe form of epilepsy characterized by multiple seizures that begin in early childhood.
The 225 patients with Lennox-Gastaut Syndrome selected for the study had two or more drop seizures per week. At the commencement of the study, the patients were split into three groups and given CBD dosages of 10 or 20 milligrams per kilogram of body weight or a placebo, twice a day for 14 weeks, in conjunction with their traditionally prescribed epilepsy medications. The patients then reported how many drop seizures they had during the treatment period.
The results of the study demonstrated that the patients receiving the 20mg/kg of body weight CBD dose had 41.9% less seizures and the patients receiving the 10mg/kg of body weight dose had 37.2% less seizures. Patient reported adverse symptoms included sleepiness, decreased appetite and diarrhea. Fourteen of the patients also had elevated liver aminotransferase concentrations (which are enzymes that catalyze a transamination reaction between an amino acid and an α-keto acid. They are important in the synthesis of amino acids, which form proteins).
The study concluded that both children and adults that received CBD, in conjunction with their traditional anti-epileptic medications, experienced a significant decrease in drop seizures during the trial with minimal adverse effects. For more information on this study, please see the link here.
Cannabis has shown to have anti-inflammatory and anti-hyperalgesia (lowering of pain response) properties, but the exact plant components causing these effects were the target of this study.
Researchers are conducting studies to examine the effect of CBD when injected directly in the hippocampus area of the brain and whether CBD could be a viable treatment therapy for depression.
Studies have shown that cannabidiol (CBD) used as an anti-depressant can be a safe and effective method of treatment. CBD is a non-psychoactive compound derived from the hemp plant which has been shown to possess antidepressant-like properties.
A group of researchers from Brazil and Denmark are conducting studies using rats to examine the effect of CBD when injected directly in the hippocampus area of the brain and whether CBD could be a viable treatment therapy for depression. The hippocampus is thought to be the center of emotion, memory and the autonomic nervous system. Specifically, the study sought to determine whether BDNF-TrkB-mTOR signaling (brain-derived neurotrophic factor/tropomyosin-receptor kinase B/mammalian target of rapamycin) in the brain plays a role in administering the effects of antidepressant drugs.
In this study, groups of rats received targeted injections of CBD directly into the hippocampus and were then subjected to a forced swim test and an open-field test to induce stress. After testing, the brain-derived neurotrophic factor (BDNF) levels were analyzed. The results showed that these direct injections of cannabidiol induced an antidepressant-like effect and increased BDNF levels. The CBD also reduced immobility time, an effect that other drugs being tested were not able to replicate.
After analysis, the researchers concluded that using the hippocampal BDNF-TrkB-mTOR pathway to inject CBD could be a vital method of treatment for depression. While further research is necessary, this targeted approach for administration is promising for those that suffer from severe depression, further demonstrating the effectiveness of CBD as a potential treatment therapy for depression.
To learn more about the medical study referenced above, please click here. https://www.ncbi.nlm.nih.gov/pubmed/29968502
A group of researchers from the United States, Canada and Italy conducted a study on rats to determine if CBD could be a viable treatment option for neuropathic pain conditions.
The administration of the CBD treatments was able to reverse the negative effects induced by iron on the brain, including cell death, and demonstrated that cannabidiol has neuroprotective properties through its ability to prevent cell death.
The results of the study demonstrated to researchers that CBD was able to realign the brain to normal levels and possibly reduce psychotic symptoms.
“Cannabidiol may not only be a faster-acting antidepressant than conventional drugs but also improve the response to such drugs when taken in combination with them.”
Brazilian and Danish scientists discovered that symptoms of depression in rats were reduced upon treatment with cannabidiol (CBD), with results lasting up to seven days. In this controlled study, researchers observed 367 rats and mice during stressful events to see if cannabidiol, given at various strengths, allowed the animals to perform better. The rats and mice that received CBD performed the tests in an anti-depressed manner, in comparison to, those that were given a placebo. One week after the initial tests were performed, various areas of the brain associated with depression were monitored; researchers found that the tested areas of the brain were functioning better after a single treatment of cannabidiol.
Researchers are continuing the scope of their study to determine if cannabidiol, in conjunction with SSRIs (selective serotonin reuptake inhibitors), will provide patients with quicker and longer-lasting relief. Traditional anti-depressants prescribed to humans often require a month to demonstrate any significant improvement and, at times, are not effective at all. Researchers believe that these patients may also be able to reduce their dosages of SSRIs while maintaining the same benefits. Researchers concluded that “cannabidiol may not only be a faster-acting antidepressant than conventional drugs but also improve the response to such drugs when taken in combination with them.” This particular study represents a breakthrough for those suffering from depression, especially those who do not respond to traditional anti-depressant therapy.
To learn more about this study, please see the link here: https://www.sciencedaily.com/releases/2018/08/180830113004.htm.
CBD has previously demonstrated immunosuppressant properties which encouraged a new study examining the effectiveness of CBD as a treatment therapy option for MS patients.
Since the discovery that the endocannabinoid system is involved in emotional memory processing, researchers have begun to examine whether cannabidiol, or CBD, could be an effective therapeutic treatment option for those suffering from PTSD.